Generic Industry’s Future May Include A Role In The Gene Therapy Space
Executive Summary
Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.
You may also be interested in...
More Than 100 Applications Lost Equivalence Rating Thanks To Allegedly Falsified Data At Two CROs
Sponsors must decide whether to repeat bioequivalence and other studies after two CROs were found to have potentially falsified data, causing the US FDA to reject all data produced by the firms.
GDUFA III Talks Completed
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.
GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements
Post-warning letter meetings for manufacturing issues and updates to the complex product meeting process are included in the user fee extension agreement.